drugset

drugset / Trial / NCT00861211

Safety and Efficacy Study of Oral Senicapoc on Allergen Challenge in Atopic Asthmatic Subjects

NCT00861211 ↗

Phase 2 Completed 34 enrolled Icagen

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to determine whether senicapoc can decrease changes in FEV1 following allergen challenge in atopic allergic subjects.

Timeline

Start: 2008-10
Primary completion: 2009-03
Completion: 2009-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Senicapoc	Small molecule	40 mg	Oral

Indications